Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kiniksa Pharmaceuticals Ltd (KNSA)

Kiniksa Pharmaceuticals Ltd (KNSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,054,548
  • Shares Outstanding, K 59,579
  • Annual Sales, $ 0 K
  • Annual Income, $ -161,870 K
  • 60-Month Beta -0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.51
  • Number of Estimates 2
  • High Estimate -0.49
  • Low Estimate -0.53
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -4.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.58 +0.68%
on 08/14/20
24.50 -27.76%
on 07/20/20
-4.29 (-19.51%)
since 07/14/20
3-Month
17.58 +0.68%
on 08/14/20
28.67 -38.26%
on 06/29/20
-3.30 (-15.71%)
since 05/14/20
52-Week
5.01 +253.29%
on 10/17/19
28.67 -38.26%
on 06/29/20
+7.01 (+65.58%)
since 08/14/19

Most Recent Stories

More News
Kiniksa Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Conference

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 2020 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2020 at 1:10 p.m. Eastern Time.

KNSA : 17.70 (-5.45%)
Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity

- Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA submission expected this year -

KNSA : 17.70 (-5.45%)
Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Upsized Public Offering

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa," "we," and "our") announced today the pricing of its public offering of 5,952,381 Class A common shares at a public offering price of $21.00 per...

KNSA : 17.70 (-5.45%)
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa," "we," and "our") announced today that it is commencing a public offering of $100.0 million of Class A common shares. In addition, Kiniksa expects...

KNSA : 17.70 (-5.45%)
Kiniksa Announces U.S. Orphan Drug Designation for Rilonacept for the Treatment of Pericarditis

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant...

KNSA : 17.70 (-5.45%)
Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY)

-- Primary and all major secondary efficacy endpoints were highly statistically significant

KNSA : 17.70 (-5.45%)
Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) ("Kiniksa"), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant...

KNSA : 17.70 (-5.45%)
Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group

Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group

CALX : 20.99 (-2.46%)
STKL : 6.78 (+1.35%)
EXPI : 34.29 (+2.08%)
ICLK : 7.96 (+0.13%)
KNSA : 17.70 (-5.45%)
5 Stocks With Recent Price Strength on Upbeat Economic Data

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

CALX : 20.99 (-2.46%)
STKL : 6.78 (+1.35%)
EXPI : 34.29 (+2.08%)
ICLK : 7.96 (+0.13%)
KNSA : 17.70 (-5.45%)
Kiniksa Provides Timing of Second Half 2020 Clinical Data Readouts

- Rilonacept pivotal Phase 3 data in recurrent pericarditis expected in Q3 2020 -

KNSA : 17.70 (-5.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade KNSA with:

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

2nd Resistance Point 19.19
1st Resistance Point 18.45
Last Price 17.70
1st Support Level 17.27
2nd Support Level 16.83

See More

52-Week High 28.67
Fibonacci 61.8% 19.63
Last Price 17.70
Fibonacci 50% 16.84
Fibonacci 38.2% 14.05
52-Week Low 5.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar